Scipher Medicine® Showcases New Data at EULAR 2024
Scipher Medicine, a company focused on proprietary AI and network biology platform solutions to transform patient care, is attending and presenting at the annual European Alliance of Associations for Rheumatology (EULAR) conference in Vienna, Austria.
- Scipher Medicine, a company focused on proprietary AI and network biology platform solutions to transform patient care, is attending and presenting at the annual European Alliance of Associations for Rheumatology (EULAR) conference in Vienna, Austria.
- The poster presentation highlighted the impact PrismRA is having on the use of biologic and targeted therapies in rheumatoid arthritis (RA).
- PrismRA, our leading AI-developed laboratory test, is used to assess non-response to tumor necrosis factor inhibitors (TNFi) in patients with RA.
- “We are pleased with the increased focus and use of PrismRA in the rheumatology community, and to be able to share this data at EULAR,” said Reginald Seeto, President and CEO of Scipher.